DBVE-PC regimen: Difference between revisions

	WikiDoc Resources for DBVE-PC regimen
Articles
Most recent articles on DBVE-PC regimen Most cited articles on DBVE-PC regimen Review articles on DBVE-PC regimen Articles on DBVE-PC regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on DBVE-PC regimen Images of DBVE-PC regimen Photos of DBVE-PC regimen Podcasts & MP3s on DBVE-PC regimen Videos on DBVE-PC regimen
Evidence Based Medicine
Cochrane Collaboration on DBVE-PC regimen Bandolier on DBVE-PC regimen TRIP on DBVE-PC regimen
Clinical Trials
Ongoing Trials on DBVE-PC regimen at Clinical Trials.gov Trial results on DBVE-PC regimen Clinical Trials on DBVE-PC regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on DBVE-PC regimen NICE Guidance on DBVE-PC regimen NHS PRODIGY Guidance FDA on DBVE-PC regimen CDC on DBVE-PC regimen
Books
Books on DBVE-PC regimen
News
DBVE-PC regimen in the news Be alerted to news on DBVE-PC regimen News trends on DBVE-PC regimen
Commentary
Blogs on DBVE-PC regimen
Definitions
Definitions of DBVE-PC regimen
Patient Resources / Community
Patient resources on DBVE-PC regimen Discussion groups on DBVE-PC regimen Patient Handouts on DBVE-PC regimen Directions to Hospitals Treating DBVE-PC regimen Risk calculators and risk factors for DBVE-PC regimen
Healthcare Provider Resources
Symptoms of DBVE-PC regimen Causes & Risk Factors for DBVE-PC regimen Diagnostic studies for DBVE-PC regimen Treatment of DBVE-PC regimen
Continuing Medical Education (CME)
CME Programs on DBVE-PC regimen
International
DBVE-PC regimen en Espanol DBVE-PC regimen en Francais
Business
DBVE-PC regimen in the Marketplace Patents on DBVE-PC regimen
Experimental / Informatics
List of terms related to DBVE-PC regimen

VisualWikitext

Latest revision as of 13:42, 11 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: ABVE-PC Regimen; Adriamycin-Bleomycin-Vincristine-Etoposide/Prednisone-Cyclophosphamide Regimen; DBVE-PC; POG 9245 Regimen

Overview

DBVE-PC regimen refers to a regimen consisting of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide, given in combination with radiation therapy and used for the treatment of high-risk, childhood Hodgkin's lymphoma.^[1]^[2]

Regimen

DDoxorubicin

BBleomycin

VVincristine

EEtoposide

PPrednisone

CCyclophosphamide

Indications

High-risk, childhood Hodgkin's lymphoma^[3]

References

↑ "NCI Thesaurus".
↑ "R-CHOP - National Cancer Institute".
↑ Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R; et al. (2009). "A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425". Blood. 114 (10): 2051–9. doi:10.1182/blood-2008-10-184143. PMC 2744567. PMID 19584400.

[1] "NCI Thesaurus".

[2] "R-CHOP - National Cancer Institute".

[pmid19584400-3] Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R; et al. (2009). "A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425". Blood. 114 (10): 2051–9. doi:10.1182/blood-2008-10-184143. PMC 2744567. PMID 19584400.

[1]

[2]

[3]

@@ Line 6: / Line 6: @@
 ==Overview==
-{{PAGENAME}} refers to a regimen consisting of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide, given in combination with radiation therapy and used for the treatment of high-risk, childhood Hodgkin's lymphoma.<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate =  | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>
+{{PAGENAME}} refers to a regimen consisting of [[doxorubicin]], [[bleomycin]], [[vincristine]], [[etoposide]], [[prednisone]] and [[cyclophosphamide]], given in combination with radiation therapy and used for the treatment of high-risk, childhood [[Hodgkin's lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate =  | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>
 ==Regimen==
-[[Rituximab|{{button|R – Rituximab}}]]
+{{chemo|D|Doxorubicin}}
-[[Cyclophosphamide|{{button|C – Cyclophosphamide}}]]
+{{chemo|B|Bleomycin}}
-[[Doxorubicin|{{button|H – Doxorubicin (Hydroxydaunomycin)}}]]
+{{chemo|V|Vincristine}}
-[[Vincristine|{{button|O – Vincristine (Oncovin)}}]]
+{{chemo|E|Etoposide}}
-[[Prednisone|{{button|P – Prednisone}}]]
+{{chemo|P|Prednisone}}
+{{chemo|C|Cyclophosphamide}}
 ==Indications==
-* [[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma, untreated]]<ref>{{Cite journal | doi = 10.1056/NEJMoa011795 | issn = 1533-4406 | volume = 346 | issue = 4 | pages = 235–242 | last = Coiffier | first = Bertrand | coauthors = Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht | title = CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | journal = The New England Journal of Medicine | date = 2002-01-24 | pmid = 11807147 }}</ref>
+* High-risk, childhood [[Hodgkin's lymphoma]]<ref name="pmid19584400">{{cite journal| author=Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R et al.| title=A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. | journal=Blood | year= 2009 | volume= 114 | issue= 10 | pages= 2051-9 | pmid=19584400 | doi=10.1182/blood-2008-10-184143 | pmc=PMC2744567 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19584400  }} </ref>
-* [[Mantle cell lymphoma]]<ref>{{Cite journal | doi = 10.1056/NEJMoa1200920 | issn = 1533-4406 | volume = 367 | issue = 6 | pages = 520–531 | last = Kluin-Nelemans | first = H. C. | coauthors = E. Hoster, O. Hermine, J. Walewski, M. Trneny, C. H. Geisler, S. Stilgenbauer, C. Thieblemont, U. Vehling-Kaiser, J. K. Doorduijn, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, P. Feugier, M. Szymczyk, M. Hallek, S. Kremers, G. Lepeu, L. Sanhes, J. M. Zijlstra, R. Bouabdallah, P. J. Lugtenburg, M. Macro, M. Pfreundschuh, V. Procházka, F. Di Raimondo, V. Ribrag, M. Uppenkamp, M. André, W. Klapper, W. Hiddemann, M. Unterhalt, M. H. Dreyling | title = Treatment of older patients with mantle-cell lymphoma | journal = The New England Journal of Medicine | date = 2012-08-09 | pmid = 22873532 }}</ref>
 ==References==